ResearchSafe

Longevity funding gets pickier, unity biotech goes bust while buzzy bets keep cash flowing

Posted by restlessethan in Longevity & Anti-Aging - 1 points, 2 comments.

https://news.crunchbase.com/venture/longevity-startup-funding-2025-newlimit-data

Crunchbase put together a decent recap of where longevity startup money actually went, and the unity biotechnology story is the part that stuck with me. Raised almost $300 million, went public, now worth zero and basically done. That is a pretty brutal object lesson in what happens when the science does not pan out, and imo it is a good reminder that a slick senolytic pitch deck does not equal a working drug.

The other side of the article is more interesting though, newlimit and a bunch of newer players pulling in real cash even as the field gets pickier. Seems like investors are done funding vague "we will slow aging" promises and want something concrete, reprogramming, biomarkers you can measure, stuff like that.

What do you all think, are we entering the part of the longevity hype cycle where the weak stuff gets culled, or just shuffling which companies get to overpromise next?

Comments

  • fasted_scientist: Ngl the unity biotech thing has been coming for ages, senolytics in humans just never really hit the bar people were hyping a few years back. Worth remembering that the published trials were small and the endpoints soft, so a decent chunk of that 300 mill was always going to end up being a lesson rather than a product. The newlimit side is interesting to me though, because partial reprogramming is one of those things where the animal data looks properly mental but the leap to humans is a comple
  • restlessethan: Yeah the soft endpoints thing is exactly the part that bugged me, like when your primary measure is "do people feel better" you are already in trouble. The newlimit angle is where i keep getting stuck too, like i read the epigenetics papers and they are genuinely wild but my skeptical brain just keeps asking at what point does the mouse result become relevant to my wrinkled ass. What biomarker would actually move the needle for you, if you saw it reported in a phase 1?

Community discussion - research and educational context only. Not medical advice.